MILESTONE trial results: MRD response-adapted deferral of autoSCT in newly diagnosed myeloma

Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients Enrolled in the Forte TrialПодробнее

The relevance of MRD assessment in the clinical management of Multiple Myeloma (MM) patientsПодробнее

What were the results of the DETERMINATION Trial presented at ASCO and EHA?Подробнее

MILESTONE Trial: MRD Adapted Deferral of Transplant in Dysproteinemia | Susan Bal, MD | IMS 2024Подробнее

Evaluating nivolumab-based therapy to restore T-cell fitness in patients with R/R multiple myelomaПодробнее

MRD evaluation in myeloma: The future is hereПодробнее

The Utility of MRD Testing for Myeloma Patient Treatment and OutcomesПодробнее

Updates from the DETERMINATION trial: RVD vs. autoSCT in patients with multiple myelomaПодробнее

MRD Evaluation in Myeloma: A necessary clinical tool?Подробнее

(RVd) ± , stem cell transplantation and R maintenance shows significance for NDMMПодробнее

Evaluating response to treatment in patients with EMDПодробнее

Measuring My Myeloma With MRD Testing: What Is My Disease State?Подробнее

Response monitoring in multiple myelomaПодробнее

Evolution of Diagnostic and Response Criteria in Multiple MyelomaПодробнее

IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma PtsПодробнее

Using MRD after autoSCT as a benchmark for consolidation strategies in myelomaПодробнее

Impact of MRD Assessment on Myeloma TreatmentПодробнее

Assessing MRD in multiple myelomaПодробнее